Newswise — June 21, 2023 – For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO) – a common complication of abnormal bone formation, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
The findings "add new clinical evidence regarding the protective role of TXA with respect to the prevention of HO after elbow trauma," according to the report by Cunyi Fan, MD, PhD, of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, China, and colleagues.
Fifty percent reduction in HO in patients receiving TXA
Heterotopic ossification refers to abnormal bone formation in the soft tissue. It is a common and potentially disabling complication following surgery for traumatic elbow fracture, with a reported prevalence of up to 40%. Inflammation is common after limb trauma and is an important factor in the initiation of HO.
TXA is increasingly used to reduce blood loss during orthopaedic surgery and has been shown to reduce inflammatory responses postoperatively. Dr. Fan and colleagues reviewed their experience to determine whether the use of TXA is associated with a lower risk of HO.
The retrospective study included two matched groups of patients with a mean age of 44 years who underwent surgery for traumatic elbow fracture. One group received TXA during surgery and the other group did not. The incidence and severity of HO were compared between groups, including adjustment for other characteristics.
The overall rate of postoperative HO was 8.71% in patients who received TXA compared with 16.18% in those who did not. On adjusted analysis, the incidence of HO was reduced by half in the TXA group, with an odds ratio of 0.49.
Anti-inflammatory effects of TXA may help to prevent HO
The incidence of clinically important HO, based on the presence of functional limitations, was 2.07% in patients who received TXA compared with 5.80% in those who did not. For this outcome, risk was reduced by two-thirds in the TXA group, with an odds ratio of 0.34. Tranexamic acid was associated with a lower risk of HO across patient subgroups with differing characteristics.
This study provides the first published evidence that using TXA during elbow trauma surgery can help lower the risk of postoperative HO. Previous reports have found that reducing inflammation can reduce HO formation – "indicating that the inflammatory response acts as a necessary starting factor for HO development," the researchers write. The authors discuss recent evidence suggesting the potential anti-inflammatory properties of TXA.
Dr. Fan and coauthors note the limitations of their retrospective analysis and highlight the need for larger studies, including those to assess laboratory markers of inflammation. In the meantime, the researchers conclude, "TXA prophylaxis may be an appropriate method for the prevention of HO following surgery for the treatment of elbow trauma."
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.